Learn how emerging biopharma companies can design flexible, risk-resistant supply chains that withstand uncertainty while ensuring product availability at launch and beyond.

This executive team will get into a dynamic discussion about:

• Why resilience matters in today’s launch environment
• How to design a flexible, risk-resistant first-launch supply chain
• Regulatory and quality readiness pitfalls that can derail launch plan
• Commercial planning watchouts and lessons learned from real-world launches

Speakers: 

• Christopher Carter, Vice President, Quality Assurance & Regulatory Affairs
• Pamela Bol, Vice President, 3PL
• Bill Little, Vice President of Business Development